

# Contents

|          |                                                                                                                                                   |           |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| <b>1</b> | <b>Epidemiology, Measurement, and Cost of Obesity</b>                                                                                             | <b>1</b>  |
|          | Obesity in Populations                                                                                                                            | 4         |
|          | Child and Adolescent Obesity                                                                                                                      | 4         |
|          | Adult Obesity                                                                                                                                     | 5         |
|          | Obesity Rates Within Minority Groups and Subpopulations                                                                                           | 7         |
|          | Measurement of Obesity                                                                                                                            | 9         |
|          | Weight Related Health Indicators (WRHI)                                                                                                           | 9         |
|          | Surveys of Health Status in the United States                                                                                                     | 15        |
|          | Healthcare Costs: The Impact of Obesity and Obesity-Related Disease                                                                               | 16        |
|          | Social, Future, and Personal Cost of Obesity                                                                                                      | 17        |
|          | Implementing Specific Process for Chapter 1 Recommendations                                                                                       | 19        |
|          | Conclusion                                                                                                                                        | 20        |
|          | References                                                                                                                                        | 20        |
| <b>2</b> | <b>Prejudice, Discrimination, and the Preferred Approach to the Patient with Obesity</b>                                                          | <b>23</b> |
|          | The Patient’s Perspective                                                                                                                         | 24        |
|          | Discrimination, Prejudice, and Weight Stigma                                                                                                      | 24        |
|          | Creating a Culture of Safety for the Patient with Obesity                                                                                         | 25        |
|          | The Current Healthcare Environment Is Prejudiced Against People with Obesity                                                                      | 25        |
|          | Changing the Current Healthcare Environment from Biased to Blameless                                                                              | 26        |
|          | The Blame Game: Why Blame the Patient for Their Obesity When We Do not Blame Them for Their Allergies, High Cholesterol, Hypertension, or Cancer? | 27        |
|          | Inability or Unwillingness to Overcome Bias Against Obesity and Its Effects                                                                       | 28        |
|          | How Obesity Bias Negatively Affects Medical Care and Outcomes                                                                                     | 29        |

|                                                                                                                                   |           |
|-----------------------------------------------------------------------------------------------------------------------------------|-----------|
| The Importance of Communicating the Measurement and Identification of Obesity of All Patients Within a Healthcare System. . . . . | 30        |
| How to Talk with Your Patient About Obesity—The Preferred Approach . . . . .                                                      | 32        |
| The Expression of Empathy. . . . .                                                                                                | 33        |
| The Development of Discrepancy. . . . .                                                                                           | 34        |
| Implementing Specific Process for Chapter Two                                                                                     |           |
| Recommendations . . . . .                                                                                                         | 35        |
| For Staff and Colleagues. . . . .                                                                                                 | 35        |
| For Patients. . . . .                                                                                                             | 36        |
| Physical Environment of the Workplace . . . . .                                                                                   | 37        |
| Conclusion . . . . .                                                                                                              | 37        |
| References. . . . .                                                                                                               | 38        |
| <b>3 The Biology of Weight Regulation and Genetic Resetting™ . . . . .</b>                                                        | <b>41</b> |
| The Canary in the Coal Mine . . . . .                                                                                             | 41        |
| The Pima Story . . . . .                                                                                                          | 42        |
| Research Results: The NIH/NIDDK and the PIMA. . . . .                                                                             | 43        |
| Fetal Programming. . . . .                                                                                                        | 45        |
| Application of Research Results to Other Populations. . . . .                                                                     | 45        |
| Calories in Do Not Equal Calories Out. . . . .                                                                                    | 46        |
| The Brain: The Control Center. . . . .                                                                                            | 47        |
| Neuroanatomy . . . . .                                                                                                            | 48        |
| Genetic Resetting™: Setting the Stage for Obesity. . . . .                                                                        | 49        |
| The Double Helix—The Human Genome . . . . .                                                                                       | 50        |
| Epigenetics and Epigenetic Modification (Genetic Resetting™) . . . . .                                                            | 51        |
| Imprinting . . . . .                                                                                                              | 51        |
| Intergenerational Metabolic Programming . . . . .                                                                                 | 51        |
| Interactome Networks in Human Disease: Obesity . . . . .                                                                          | 54        |
| The Gut Brain Axis (GBA): Signals from the Gut to the Brain . . . . .                                                             | 55        |
| The Microbiome and Microbiota . . . . .                                                                                           | 55        |
| Why Eat? . . . . .                                                                                                                | 57        |
| Hormone Signals to the Brain . . . . .                                                                                            | 57        |
| Taste—Not All in Your Mouth . . . . .                                                                                             | 58        |
| Ghrelin: The “I’m Hungry” Hormone . . . . .                                                                                       | 58        |
| Glucagon-Like Peptide-1 (GLP-1) . . . . .                                                                                         | 59        |
| Insulin . . . . .                                                                                                                 | 59        |
| Cognitive Function and Glucose-Related Signaling. . . . .                                                                         | 60        |
| Signaling Through the Nervous System. . . . .                                                                                     | 60        |
| The Sympathetic Nervous System (SNS). . . . .                                                                                     | 62        |
| Parasympathetic Nervous System: The Vagus Nerve. . . . .                                                                          | 63        |
| The Second Brain: The Enteric Nervous System (ENS). . . . .                                                                       | 63        |
| Conclusion . . . . .                                                                                                              | 63        |
| References. . . . .                                                                                                               | 63        |

|          |                                                                                                                                                                                |     |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| <b>4</b> | <b>The Biology of Adipose Tissue.</b>                                                                                                                                          | 67  |
|          | Adipose Tissue: Energy Storage and Endocrine Signaling                                                                                                                         | 68  |
|          | The Development of Adipose Tissue                                                                                                                                              | 68  |
|          | The Structure of Adipose Tissue                                                                                                                                                | 69  |
|          | The Adipocyte.                                                                                                                                                                 | 69  |
|          | Brown Adipose Tissue (BAT)                                                                                                                                                     | 69  |
|          | White Adipose Tissue (WAT)                                                                                                                                                     | 69  |
|          | Macrophages                                                                                                                                                                    | 71  |
|          | Extracellular Matrix (ECM)                                                                                                                                                     | 71  |
|          | Adipose Tissue Blood Flow and Innervation                                                                                                                                      | 71  |
|          | Lipogenesis and Lipolysis: How Fat Is Stored                                                                                                                                   |     |
|          | and How It Is Used For Energy                                                                                                                                                  | 72  |
|          | The Tipping Point: Inflammation and Adipose Tissue Dysfunction                                                                                                                 | 73  |
|          | Hypoxia and Inflammation in White Adipose Tissue.                                                                                                                              | 74  |
|          | Adipokines: Leptin and Adiponectin.                                                                                                                                            | 76  |
|          | Leptin.                                                                                                                                                                        | 76  |
|          | Leptin Resistance.                                                                                                                                                             | 78  |
|          | Adiponectin.                                                                                                                                                                   | 78  |
|          | Conclusion                                                                                                                                                                     | 79  |
|          | References.                                                                                                                                                                    | 80  |
| <b>5</b> | <b>Obesity-Related Diseases and Syndromes: Insulin Resistance, Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Cardiovascular Disease, and Metabolic Syndrome</b> | 83  |
|          | Insulin Resistance.                                                                                                                                                            | 84  |
|          | How to Assess a Patient for Insulin Resistance                                                                                                                                 | 86  |
|          | Mechanisms of Insulin Resistance                                                                                                                                               | 87  |
|          | Inflammation and Insulin Resistance.                                                                                                                                           | 90  |
|          | Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT), and Prediabetes                                                                                              | 90  |
|          | Type 2 Diabetes Mellitus (T2DM)                                                                                                                                                | 92  |
|          | Metabolic Syndrome.                                                                                                                                                            | 93  |
|          | Non-Alcoholic Fatty Liver Disease (NAFLD), Steatohepatitis (NASH) and Cirrhosis                                                                                                | 95  |
|          | The Role of Microbiota, Intestinal Dysbiosis, and Metabolic Endotoxemia in NAFLD                                                                                               | 95  |
|          | Obesity-Related Cardiovascular Disease                                                                                                                                         | 97  |
|          | The Obesity Paradox                                                                                                                                                            | 97  |
|          | Dyslipidemia                                                                                                                                                                   | 98  |
|          | Hypertension                                                                                                                                                                   | 99  |
|          | Atherosclerosis, Coronary Heart Disease (CHD), and Heart Failure                                                                                                               | 101 |

|                                                                                                                                                    |            |
|----------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Atrial Fibrillation and Stroke . . . . .                                                                                                           | 101        |
| Heart Failure . . . . .                                                                                                                            | 102        |
| Conclusion . . . . .                                                                                                                               | 103        |
| References. . . . .                                                                                                                                | 103        |
| <b>6 Obesity-Related Diseases and Syndromes: Cancer, Endocrine Disease, Pulmonary Disease, Pseudotumor Cerebri, and Disordered Sleep . . . . .</b> | <b>109</b> |
| Obesity and Cancer . . . . .                                                                                                                       | 110        |
| Mechanisms of Cancer Growth and Promotion in Patients with Obesity . . . . .                                                                       | 111        |
| Obesity and Breast Cancer . . . . .                                                                                                                | 114        |
| The Challenge of Diagnosing and Treating Cancer in the Patient with Obesity . . . . .                                                              | 116        |
| Obesity and Endocrine Disease . . . . .                                                                                                            | 116        |
| Obesity and Thyroid Hormones . . . . .                                                                                                             | 116        |
| Obesity and Polycystic Ovarian Syndrome . . . . .                                                                                                  | 117        |
| Obesity and Infertility. . . . .                                                                                                                   | 118        |
| Obesity and Pulmonary Disease . . . . .                                                                                                            | 119        |
| Abnormalities of Pulmonary Function. . . . .                                                                                                       | 119        |
| Asthma . . . . .                                                                                                                                   | 119        |
| Obesity Hyperventilation Syndrome . . . . .                                                                                                        | 119        |
| Venous Thromboembolic Disease. . . . .                                                                                                             | 120        |
| Obesity and Pseudotumor Cerebrii . . . . .                                                                                                         | 121        |
| Disordered Sleep . . . . .                                                                                                                         | 121        |
| Circadian Rhythm . . . . .                                                                                                                         | 122        |
| Sleep . . . . .                                                                                                                                    | 123        |
| Owl or Lark?. . . . .                                                                                                                              | 123        |
| Insomnia and Stress . . . . .                                                                                                                      | 125        |
| Obstructive Sleep Apnea. . . . .                                                                                                                   | 126        |
| Conclusion . . . . .                                                                                                                               | 127        |
| References. . . . .                                                                                                                                | 127        |
| <b>7 Pediatric Obesity . . . . .</b>                                                                                                               | <b>133</b> |
| Scope of the Epidemic . . . . .                                                                                                                    | 134        |
| Genetic Influence on Childhood Obesity . . . . .                                                                                                   | 135        |
| Types of Childhood Obesity . . . . .                                                                                                               | 137        |
| Common Obesity . . . . .                                                                                                                           | 138        |
| Syndromic Obesity. . . . .                                                                                                                         | 138        |
| Non-syndromic Obesity . . . . .                                                                                                                    | 139        |
| Clinical Consequences of Childhood Obesity. . . . .                                                                                                | 139        |
| Disordered Sleep . . . . .                                                                                                                         | 141        |

|                                                                                        |            |
|----------------------------------------------------------------------------------------|------------|
| Respiratory Problems in Children with Obesity . . . . .                                | 142        |
| Gastrointestinal Problems in Children with Obesity . . . . .                           | 142        |
| Endocrine Disorders in Children with Obesity . . . . .                                 | 143        |
| Clinical Assessment of Children with Overweight/Obesity . . . . .                      | 148        |
| Biobehavioral Susceptibility Model of Child Obesity . . . . .                          | 152        |
| Treatment Recommendations for Children with Obesity . . . . .                          | 153        |
| Stage 1: Prevention Plus . . . . .                                                     | 154        |
| Stage 2: Structured Weight Management . . . . .                                        | 156        |
| Stage 3: Comprehensive Multidisciplinary Program . . . . .                             | 156        |
| Stage 4: Tertiary Care . . . . .                                                       | 157        |
| Conclusion . . . . .                                                                   | 162        |
| References . . . . .                                                                   | 162        |
| <b>8 Fundamentals of Diet, Exercise, and Behavior Modification . . . . .</b>           | <b>167</b> |
| Food and Digestion . . . . .                                                           | 168        |
| Digestion . . . . .                                                                    | 168        |
| Recommended Mechanics of Eating . . . . .                                              | 169        |
| Calories and Kilocalories . . . . .                                                    | 170        |
| Macronutrients . . . . .                                                               | 170        |
| Reading a Food Label . . . . .                                                         | 179        |
| Energy Expenditure . . . . .                                                           | 180        |
| Energy Expenditure: Basal Metabolic Rate (BMR) . . . . .                               | 180        |
| Energy Expenditure: Thermal Effect of Food (TEF) . . . . .                             | 180        |
| Energy Expenditure: Thermogenesis<br>(Exercise and Physical Activity) . . . . .        | 181        |
| Mental Health in the Bariatric Population . . . . .                                    | 183        |
| Specific Psychiatric Disorders Related to Obesity:                                     |            |
| Depression and Anxiety . . . . .                                                       | 184        |
| Food Addiction: Science or Silly? . . . . .                                            | 185        |
| Conclusion . . . . .                                                                   | 190        |
| References . . . . .                                                                   | 190        |
| <b>9 The Assessment of the Adult Patient with Overweight<br/>and Obesity . . . . .</b> | <b>193</b> |
| The Health History . . . . .                                                           | 195        |
| Historical Survey of Weight Gain and Loss . . . . .                                    | 196        |
| Family History of Obesity and Related Disease . . . . .                                | 196        |
| Medications . . . . .                                                                  | 196        |
| Dietary History . . . . .                                                              | 199        |
| Stress Factors . . . . .                                                               | 199        |
| Circadian Patterns . . . . .                                                           | 202        |
| Disordered Sleep Analysis . . . . .                                                    | 202        |
| Lifestyle, Cultural, and Occupational Factors . . . . .                                | 203        |
| Physical Activity . . . . .                                                            | 204        |
| Obesity-Related Disease . . . . .                                                      | 205        |

|                                                                                                                 |            |
|-----------------------------------------------------------------------------------------------------------------|------------|
| Psychosocial and Psychiatric History . . . . .                                                                  | 216        |
| Surgical History . . . . .                                                                                      | 216        |
| Allergies . . . . .                                                                                             | 216        |
| Review of Systems . . . . .                                                                                     | 218        |
| Physical Assessment of Patients with Obesity<br>and Related Diseases . . . . .                                  | 219        |
| Anthropometrics . . . . .                                                                                       | 219        |
| Pattern of Body Fat Distribution . . . . .                                                                      | 219        |
| Vital Signs . . . . .                                                                                           | 220        |
| General Observation . . . . .                                                                                   | 220        |
| Head, Eyes, Ears, Nose and Throat . . . . .                                                                     | 220        |
| Chest and Breast Exam . . . . .                                                                                 | 221        |
| Abdomen . . . . .                                                                                               | 221        |
| Extremities . . . . .                                                                                           | 222        |
| Neurologic . . . . .                                                                                            | 223        |
| Pelvic and Anorectal Exam . . . . .                                                                             | 223        |
| Skin, Trunk, and Extremities . . . . .                                                                          | 223        |
| Determination of Metabolic Factors . . . . .                                                                    | 224        |
| Resting Metabolic Rate . . . . .                                                                                | 224        |
| Body Composition Analysis . . . . .                                                                             | 224        |
| Diagnostic Tests for Obesity-Related Disease . . . . .                                                          | 225        |
| Conclusion: The Summary Assessment Based on History,<br>Physical Exam and Diagnostic Testing . . . . .          | 227        |
| References . . . . .                                                                                            | 228        |
| <b>10 Beyond Traditional Management: The Use of Medications<br/>in the Treatment of Obesity . . . . .</b>       | <b>231</b> |
| The Use of Medications for the Treatment of <i>Other</i> Medical<br>Problems in Patients with Obesity . . . . . | 232        |
| Medications that Cause Weight Gain . . . . .                                                                    | 236        |
| Medications for Use as Weight Loss Medications . . . . .                                                        | 239        |
| Historical Perspective of Weight Loss Medications . . . . .                                                     | 239        |
| Indications for the Use of Prescription Medications<br>in a Patient with Obesity . . . . .                      | 241        |
| Medications Currently Approved for the Treatment of Obesity . . . . .                                           | 244        |
| Phentermine . . . . .                                                                                           | 245        |
| Lorcaserin (Belviq) . . . . .                                                                                   | 246        |
| Liraglutide (Saxenda) . . . . .                                                                                 | 249        |
| Orlistat (Xenical, Alli) . . . . .                                                                              | 252        |
| Phentermine/Topiramate (Qnexa, Qsymia) . . . . .                                                                | 252        |
| Naltrexone SR/Bupropion SR (NB) (CONTRAVE) . . . . .                                                            | 254        |
| Nutraceuticals . . . . .                                                                                        | 257        |
| Medications as Related to Bariatric Surgery . . . . .                                                           | 257        |
| Conclusion . . . . .                                                                                            | 258        |
| References . . . . .                                                                                            | 258        |

|                                                                              |     |
|------------------------------------------------------------------------------|-----|
| <b>11 Bariatric Surgery</b> . . . . .                                        | 261 |
| National Accreditation in Metabolic and Bariatric Surgery. . . . .           | 263 |
| Indications/Contraindications for Surgery. . . . .                           | 264 |
| Mechanism of Action of MBS. . . . .                                          | 266 |
| Epigenetic Changes . . . . .                                                 | 267 |
| Enteroplasticity . . . . .                                                   | 267 |
| Changes in Reward Pathways . . . . .                                         | 269 |
| Changes in Energy Expenditure . . . . .                                      | 270 |
| Metabolic and Bariatric Surgery: Procedures and Devices . . . . .            | 271 |
| Laparoscopic Roux-en Y Gastric Bypass (LRYGB) . . . . .                      | 272 |
| Laparoscopic Sleeve Gastrectomy (LSG). . . . .                               | 277 |
| Laparoscopic Adjustable Gastric Band (LAGB) . . . . .                        | 279 |
| Duodenal Switch/Biliopancreatic Diversion (DS/BPD) . . . . .                 | 282 |
| Gastric Balloon (GB) and the Vagal Blocking<br>Device (VBLOC). . . . .       | 284 |
| Variability in Response to Metabolic and Bariatric Surgery:                  |     |
| Weight Regain. . . . .                                                       | 286 |
| Cholecystectomy After Metabolic and Bariatric Surgery . . . . .              | 287 |
| Prehabilitation: Preoperative Assessment and Preparation . . . . .           | 288 |
| Education and Informed Consent . . . . .                                     | 289 |
| Physical Assessment for Surgery . . . . .                                    | 290 |
| Social and Psychological Health Assessment Prior to Surgery . . . .          | 292 |
| Enhanced Recovery After Metabolic and Bariatric Surgery . . . . .            | 294 |
| Preoperative Prehabilitation . . . . .                                       | 295 |
| Perioperative . . . . .                                                      | 295 |
| Postoperative . . . . .                                                      | 295 |
| Health Maintenance After Metabolic and Bariatric Surgery . . . . .           | 296 |
| Conclusion . . . . .                                                         | 297 |
| References. . . . .                                                          | 297 |
| <b>12 Population Health Management of Obesity</b> . . . . .                  | 307 |
| Barriers. . . . .                                                            | 309 |
| Accurate Measurement of Obesity Is Essential. . . . .                        | 309 |
| Politicizing Obesity Prevents Action. . . . .                                | 309 |
| Prevention Versus Recognition and Treatment<br>of Existing Disease. . . . .  | 310 |
| The Epidemic of Obesity Is a Social Disease. . . . .                         | 311 |
| A New Paradigm: Management of Obesity, not Acceptance<br>of Obesity. . . . . | 311 |
| Recognition. . . . .                                                         | 313 |
| Measure Every Patient, Every Time . . . . .                                  | 313 |
| Communicate Level of Risk to Each Patient . . . . .                          | 314 |
| Education . . . . .                                                          | 315 |

|                                              |            |
|----------------------------------------------|------------|
| Engagement. . . . .                          | 317        |
| Keys to Personal Engagement . . . . .        | 317        |
| Risk Groups in the New Paradigm . . . . .    | 318        |
| Measuring Value . . . . .                    | 320        |
| Population Health and Public Policy. . . . . | 322        |
| Conclusion . . . . .                         | 324        |
| References. . . . .                          | 324        |
| <b>Index . . . . .</b>                       | <b>327</b> |

## Obesity

The Medical Practitioner's Essential Guide

Blackstone, R.P.

2016, XX, 337 p. 60 illus., 40 illus. in color., Softcover

ISBN: 978-3-319-39407-7